# RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

> **NCT06397313** · PHASE2 · RECRUITING · sponsor: **Ryvu Therapeutics SA** · enrollment: 230 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** RVU120
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT06397313
- **Lead sponsor:** Ryvu Therapeutics SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2026-06
- **Final completion:** 2027-10
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06397313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06397313, "RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06397313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*